Is Eli Lilly’s Jaypirca now the most compelling single-agent therapy in untreated CLL?
Lilly’s Jaypirca reduced progression risk by 80% in frontline CLL. Explore what this changes for therapy sequencing, safety, and BTK inhibitor strategy.
Lilly’s Jaypirca reduced progression risk by 80% in frontline CLL. Explore what this changes for therapy sequencing, safety, and BTK inhibitor strategy.